Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
8.68
+0.79 (10.01%)
At close: Mar 9, 2026, 4:00 PM EDT
8.66
-0.02 (-0.23%)
After-hours: Mar 9, 2026, 7:14 PM EDT
Vanda Pharmaceuticals Employees
Vanda Pharmaceuticals had 533 employees as of December 31, 2025. The number of employees increased by 165 or 44.84% compared to the previous year.
Employees
533
Change (1Y)
165
Growth (1Y)
44.84%
Revenue / Employee
$405,450
Profits / Employee
-$413,647
Market Cap
513.06M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| REGENXBIO | 353 |
| Lyell Immunopharma | 300 |
| Rocket Pharmaceuticals | 202 |
| Entrada Therapeutics | 152 |
| Century Therapeutics | 150 |
| Kyverna Therapeutics | 129 |
| Lineage Cell Therapeutics | 77 |
| Assembly Biosciences | 73 |
VNDA News
- 6 days ago - Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years - PRNewsWire
- 11 days ago - Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference - PRNewsWire
- 12 days ago - Vanda Pharmaceuticals Breaks Through With FDA Approval, Decision Date For Skin Drug - Benzinga
- 12 days ago - Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis - PRNewsWire
- 14 days ago - Vanda Pharmaceuticals: Soaring On Bysanti Approval, But You Shouldn't Feel Dizzy - Seeking Alpha
- 14 days ago - Vanda Pharmaceuticals stock's explosive rally may be more hype than substance - Invezz
- 14 days ago - Vanda Pharmaceuticals FDA Approval Dawns A New Era For Bipolar And Schizophrenia Treatment - Benzinga
- 17 days ago - US FDA approves Vanda's psychiatric drug - Reuters